Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML.
The company was founded in 2007 and is based in Bellaire, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -4.88 Decreased by -639.39% | -4.54 Decreased by -7.49% |
| Jan 30, 24 | -7.05 Decreased by -1.26 K% | -5.40 Decreased by -30.56% |
| Nov 13, 23 | -0.32 Increased by +34.69% | -0.34 Increased by +5.88% |
| Aug 14, 23 | -0.53 Decreased by -26.19% | -0.52 Decreased by -1.92% |
| May 11, 23 | -0.66 Decreased by -40.43% | -0.45 Decreased by -46.67% |
| Mar 31, 23 | -0.52 Increased by +11.86% | -0.45 Decreased by -15.56% |
| Nov 14, 22 | -0.49 Decreased by -68.97% | -0.45 Decreased by -8.89% |
| Aug 15, 22 | -0.42 Decreased by -61.54% | -0.49 Increased by +14.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Decreased by N/A% | -3.37 M Increased by +14.55% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.20 M Increased by +9.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.23 M Decreased by -40.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.25 M Decreased by -56.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.95 M Increased by +4.13% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -3.52 M Decreased by -70.32% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -3.01 M Decreased by -66.26% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -3.36 M Decreased by -37.27% | Decreased by N/A% Decreased by N/A% |